#TestMeFirst SURVIVEiT® Patient Awareness Campaign

#TestMeFirst SURVIVEiT® Patient Awareness Campaign

Cancer research is changing rapidly and it’s vital for patients to have comprehensive genomic profiling of their cancers. With this information, patients can advocate for the most complete range of options and personalized care offering the hope of a longer and higher quality of life.

Trial by Fire: How to Action N-of-1 Clinical Trials for Cancer Patients

Trial by Fire: How to Action N-of-1 Clinical Trials for Cancer Patients

The availability of and correct interpretation of next-generation sequencing results gives the physician the information she or he needs to help the patient be an N-of-1 trial.  Decision support tools make this decision possible at point-of-care; the physician can easily be made aware of the drivers, the potential targeted therapies and have the tools to apply, monitor and manage the patient throughout her or his treatment. These can then be compared to results the intervention achieves in other patients who have the same genomic driver regardless of what site the cancer is first reported in (e.g. if the same gene is driving lung cancer and colon cancer in different patients does the drug work in both?)

Matching, notification, treatment management and data collection becomes a much simpler and manageable problem for an AI platform that “thinks” like a doctor and applies sound logic and medical management rules.  VieCure’s platform was built to address this need, literally in seconds, when the physician requires it.

Factorial Complexity in Cancer Care is Here and Overwhelms!

Factorial Complexity in Cancer Care is Here and Overwhelms!

Genomics-based research is advancing at a pace that it is difficult for any cancer practitioner to interpret, absorb and action. The growing list of biomarker-driven care options compounds the already complex list of factors required for efficient and effective decisions to be made at point of care.

Research in cancer care is at an all-time fever pitch. The Scopus database shows more than 1 million peer-reviewed publications and scientific proceedings on the topic of cancer research since 2008. How can any single physician or practice stay current, sift through and select from this vast library, and ultimately make safe sense of it for her/his patients?

From 1997 to 2003, there were only 27 new cancer drugs approved by the FDA.  From 2004 to 2011, there were another 30. From 2011 to 2017, 92 more were approved.  In 2017, there were more than 630 cancer drugs in late stage clinical trials.

Bundle Blocks 2

VieCure Welcomes New Chief Technology Officer

Steven Malme will Lead Engineering, Research & Development for the VieCure Precision Medical Platform

Malme comes to VieCure from Microsoft where he led Corporate Accounts and Partner Sales in Asia, driving sales performance and an optimal customer experience. He held this same leadership position for Europe, the Middle East & Africa, driving double-digit revenue growth and launching the cloud transformation across Microsoft’s sales team and partner channel. Microsoft offered him the opportunity to work in many senior leadership roles including assuming global responsibility for health care industry sales and Dynamics partners.

Storm Warning: Old Ways Will Fail in Cancer Care

Storm Warning: Old Ways Will Fail in Cancer Care

Streamlining care with AI decision-support tool.

By 2026, there will be ~26 million cancer survivors in America, and more than 2.1 million people who will be newly diagnosed with some form of cancer. Alarmingly, by this timeframe, about 25% of oncologists will be retiring and given current and projected enrollments in medical school, the replacement rate of oncologists will be only 13%.

This means by 2026 that 1.9M - 4.5M Americans who have new cancer or require cancer follow-up will not have access to an oncologist, given currently accepted care delivery models and capacity metrics for oncologists.  These estimates do not take into account that 80% of cancer patients are seen by community oncologists who are already operating over capacity.

Intelligent Mobile App Keeps Cancer Patients Out of the ER

Intelligent Mobile App Keeps Cancer Patients Out of the ER

Intelligent mobile app will improve communications between cancer patients and providers and reduce ER visits.

Nonadherence to treatment plans is estimated to account for as much as 50 percent of treatment failures overall, and even for cancer patients, whose lives are on the line, adherence can be as low as 14 percent. Technology can help head-off these negative outcomes.

Cancer patients become overwhelmed. The complexity and volume of daily medications and symptom monitoring, while they are experiencing life-altering emotional and physical changes, is the perfect setup for mistakes, oversights, stress and hopelessness. Intelligent mobile technology can break these daily tasks into bite-size pieces and deliver them at the right time, relieving a patient’s responsibility to constantly monitor all facets of their care. 

Bundle Blocks 1

National Cancer Control Month

Patient Resources - SURVIVEiT®

In honor of National Cancer Control Month, we honor those we love who have battled cancer and the survivors who continue the fight. We also thank the healthcare professionals who care for patients and those working toward a cure. 

Our friends at SURVIVEiT® have developed patient resources that have been reviewed and approved as "best in class" by Team SURVIVEiT®'s medical and survivor advisory boards.

Visit their cancer resources page to find related medical, financial, and support resources specific to each type of cancer.

SURVIVEiT® is a global community of survivors, doctors, experts, and allies who provide hope, knowledge, and resources crucial to surviving cancer.

After receiving a cancer diagnosis, the most important, urgent question to ask is, "What’s next?" SURVIVEiT® provides the answer.

CMS decision transformative for cancer care

CMS decision transformative for cancer care

The Centers for Medicare & Medicaid Services’ (CMS) decision to reimburse for Next Generation Sequencing (NGS) for patients with advanced cancer is a major step to realizing personalized cancer treatment. This reimbursement approval fits perfectly with the expanding use of VieCure’s comprehensive platform for precision cancer care that optimally utilizes NGS within its proprietary VCureEyellation AI engine.   

Genomics-based research is advancing quickly, that makes it difficult for cancer practitioners to keep up.  The basis of precision, or personalized, medicine is understanding the unique cellular mutations that are driving each person’s cancer.  NGS is a major step forward to know a cancer patient’s unique type of cancer.  Medicare has recognized that knowing the drivers of each person’s cancer is beneficial to treating advanced stage cancers.  VieCure uses sequencing data to generate personalized and comprehensive care plans curated by the world’s top research scientists.  Reimbursement by Medicare will continue the path of broad adoption of NGS and precision care.

Baptist Health to Improve Cancer Care with VCurePrecision™ AI Platform

Baptist Health to Improve Cancer Care with VCurePrecision™ AI Platform

MONTGOMERY, AL (March 5, 2018) (VieCure and related products are the property of Viviphi Ltd) VieCure and Baptist Health announced today that the VCurePrecision platform will be deployed across the central Alabama cancer network, offering personalized cancer treatment to an estimated 4,000 patients annually throughout the region.  

Baptist Health is a 689-licensed-bed and accredited health system in Montgomery and is the largest provider of cancer services in central Alabama. They have committed to advancing the care offered to cancer and hematology patients through the AI platform developed by VieCure.   

The VCurePrecision platform allows clinicians to generate and manage comprehensive, personalized care plans in real time. Powered by the Eyellation™ inference engine, the platform combines patient-specific data with expert codified knowledge to create and manage personalized and actionable treatment plans based on nationally and internationally-accepted standards of care, including the latest genomic-based considerations where and when appropriate.

Avera Health to lead new clinical trial for non-small cell lung cancer patients

Avera Health to lead new clinical trial for non-small cell lung cancer patients

Our friends at Avera Health will lead a new clinical trial for non-small cell lung cancer patients.

As a world leader in precision medicine dedicated to improving outcomes in patients with cancer, they will be the first to enroll patients in the Survival Prolongation by Rationale Innovative Genomics (SPRING) trial.

Patients will receive a three-drug protocol that incorporates immunotherapy and two targeted therapies. The FDA approved trial is Avera’s latest collaboration as part its membership in the Worldwide Innovative Networking (WIN) Consortium.

VieCure and Avera Health Confirm Clinical Validation and System-Wide Implementation of AI Platform

VieCure and Avera Health Confirm Clinical Validation and System-Wide Implementation of AI Platform

VieCure (Greenwood Village, CO) and Avera Health (Sioux Falls, SD) announced today that the VCurePrecision™ platform will be fully implemented across the multi-state cancer system. The platform was developed through a clinical collaboration between the two organizations.

VCurePrecision™ is an AI platform that generates comprehensive, actionable and patient-specific treatment plans in a matter of seconds. It combines patient-specific diagnostic, surgical and demographic data from the electronic medical record (EMR) with codified expert knowledge to generate personalized treatment plans that comply with nationally respected evidence and the latest clinical guidance.

VieCure Announces Appointment of Howard L. McLeod, PharmD, to the Position of Senior Research Advisor in Precision Medicine

VieCure Announces Appointment of Howard L. McLeod, PharmD, to the Position of Senior Research Advisor in Precision Medicine

VieCure (Greenwood Village, CO) announced the appointment of Dr. Howard McLeod, to the position of Senior Research Advisor in Precision Medicine.  McLeod will also join the VieCure Clinical Advisory Board.   He is well known to the Precision Medicine community given his leadership responsibilities for the Department of Individualized Cancer Management at the H. Lee Moffitt Cancer Center in Tampa Bay, Florida.

In his role with VieCure, Dr. McLeod will assist in translating research and clinical advances in precision medicine in oncology.  He will help to drive the VieCure technology roadmap and will function as an active ambassador of the Company and the VCurePrecision™ AI platform at national and international research and clinical symposia.

VieCure Appoints Pradip De, PhD, to the Position of Director, Translational Oncology

VieCure Appoints Pradip De, PhD, to the Position of Director, Translational Oncology

VieCure Ltd (Greenwood Village, CO) announced the appointment of Dr. Pradip De to the position of Director of Translational Oncology.   Dr. De is the Senior Scientist and Head of Translational Oncology at the Avera Cancer Institute Center for Precision Oncology. He holds the position of Assistant Professor in the Department of Internal Medicine at the University of South Dakota Sanford School of Medicine.

In his role with VieCure, and in light of his superb comprehension of oncogenic signaling pathways, Dr. De will support the development, maintenance, testing and validation of sequence-guided oncology treatment rules. These codified clinical rules enable the translation of patient specific data into actionable knowledge for physicians. VieCure has created an AI platform that produces actionable and patient-specific treatment plans in real time.

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

Avera Innovations in the Management of Cancer Conference – A Focus on Breast

National and international experts will convene at Avera in Sioux Falls, South Dakota to discuss the latest techniques in breast cancer treatment.

Designed to provide surgeons, radiation oncologists and medical oncologists practice innovations from national and international experts on topics of electron based intra-operative radiation therapy, genomic targeted therapy and oncoplastic surgery techniques.

The conference will focus on the role of genomics, oncoplastic surgery techniques, electron-based intraoperative radiation therapy, neoadjuvant chemotherapy, and the future of surgery and radiation oncology. Attendees will include Surgeons, Radiation Oncologists, Medical Oncologists, and representatives from pharmaceuticals.

The course directors include Julie Reiland, MD, FACS, who specializes in breast cancer treatment and technology at Avera, and Brian Leyland-Jones, MB BS PhD, Vice President of Avera Cancer Institute for Precision Oncology and Vice President of Molecular and Experimental Medicine at Avera.

VieCure and Avera Health Announce a Strategic Collaboration Agreement for Precision Medicine

VieCure and Avera Health Announce a Strategic Collaboration Agreement for Precision Medicine

DENVER — (December 15, 2016) — VieCure and Avera Health (Sioux Falls, SD) announced today a first-of-its-kind clinical collaboration in personalized medicine for oncology.  The strategic collaboration will combine Avera’s world leading position in evidence-based knowledge and practical application of genomic-based precision medicine for cancer patients with VieCure’s AI platform.  Avera’s preeminent molecular cancer knowledge, along with nationally accepted standards of care, will be made accessible, in real time, to patients and treatment teams around the world through the VCurePrecision™ platform.

Precision Medicine World Conference

Precision Medicine World Conference

Dr. Howard McLeod from the Moffitt Cancer Center and Dr. Fred Ashbury, Chief Scientific Officer at VieCure, will host a discussion on the challenges and lessons learned to implement a precision medicine program in oncology at the Precision Medicine World Conference at Duke University on Wednesday, May 24.

Session Synopsis: Precision Medicine (PM) leaders will discuss issues and lessons learned implementing PM programs as well as opportunities for community oncology practices. Topics include: requirements for creating a precision medicine program (personnel, supports); working with sequencing labs;interpreting results; and tools needed to scale and bring genomic-guided therapies to physicians and patients. A presentation of the VCurePrecision™ platform to facilitate patient-specific genomic-guided treatment plans at point-of-care in real-time will support the discussion.